Cardiovascular Diseases Clinical Trial
Official title:
A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial Comparing Two Doses of VF001-DP to Placebo as an Adjunct to Standard Care in Patients With Chronic Venous Leg Ulcers
The purpose of this study is to determine if VF001-DP improves wound healing in chronic venous leg ulcers compared to standard care only.
Objective: The objective of this study is to demonstrate the effectiveness and safety of
VF001-DP as an adjunct to standard care (SC) in the treatment of chronic venous leg ulcers
(VLUs) compared to Placebo with SC over the course of the 12‑week Treatment Phase.
Design: This study is a multi-center, randomized, double-blind, placebo-controlled
dose‑response study designed to evaluate VF-001-DP as an adjunct to SC, versus Placebo and SC
in the treatment of chronic VLUs. The SC therapy for VLUs is a moisture retentive ulcer
dressing and multi‑layer compression therapy. Mepitel® and Coban2® have been chosen to be
used as SC in this trial.
The study will have three (3) phases: Screening (2 weeks), Treatment Phase (12 weeks) and
Follow-Up (12 weeks).
Only patients whose study ulcer does not exhibit more than 30% change (increase or decrease)
in ulcer size post-debridement between Screening Phase Visit (S1) and Treatment Phase Visit
(T1) and who continue to meet eligibility criteria at T1 will be randomized to receive either
the Active Treatment group (VF001-DP low or high dose plus SC) or the Control Treatment group
(Placebo plus SC) in a ratio of 1:1:1.
Treatment: Eligible patients will be assigned to one of the following treatment groups:
- Placebo and SC
- VF001-DP (14 micrograms per treatment) and SC (low dose [LD])
- VF001-DP (140 micrograms per treatment) and SC (high dose [HD]).
The investigational product (IP), i.e., VF001-DP and placebo, will be supplied in 1 mL
syringes each containing 0.5 mL of either VF001-DP or Placebo.
The IP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined
in a single protein (vitronectin, amino acids 1-64 of the human sequence and IGF-I amino
acids 1‑70 of the human sequence), 14 μg or 140 μg protein in 0.5 mL of Phosphate Buffered
Saline, pH 7.2. VF001-DP is manufactured utilizing an expression vector system in yeast to
Good Manufacturing Practice (GMP) and is not made with and does not include any products of
human or animal origin.
Number of Patients: It is planned to recruit 168 patients (56 per treatment group) at 26
centres in USA for this study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|